Cellular release profiling of controlled release dry powder pulmonary formulation

Virginia Commonwealth University
Publication Type:
Conference Proceeding
RDD Europe 2011, 2011, pp. 1 - 4
Issue Date:
Filename Description Size
Thumbnail2011003680OK.pdf Published version382.05 kB
Adobe PDF
Full metadata record
Respiratory tract infections (RTI), such as pneumonia, are very common and their treatments represent the largest proportion of the antibacterial market. Rapid pulmonary antibiotic absorption and clearance suggest controlled release (CR) inhaled antibiotic formulations would be beneficial for the treatment of chronic infections. To date, there is no pharmacopoeia methodology for the evaluation of in vitro drug release of respiratory formulations. This could be attributed to the lack of predictability and correlation between available in vitro and in vivo models for pulmonary drugs. Hence, to effectively predict the pharmacokinetics of drugs delivered to the lungs, a model of the airway epithelium is proposed to reflect the transport characteristics in vivo. Ciprofloxacin was chosen as a model drug.
Please use this identifier to cite or link to this item: